Skip to main content

Drug Interactions between pitolisant and sacituzumab govitecan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

pitolisant sacituzumab govitecan

Applies to: pitolisant and sacituzumab govitecan

GENERALLY AVOID: Coadministration with inducers of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) may significantly decrease the plasma concentrations of sacituzumab govitecan and its pharmacologically active metabolite, SN-38. The proposed mechanism involves decreased exposure to SN-38, a topoisomerase I inhibitor linked to sacituzumab govitecan, which is metabolized via UGT1A1. Loss of antineoplastic efficacy may occur.

MANAGEMENT: Due to the potential loss of antitumour activity, concomitant use of sacituzumab govitecan with UGT1A1 inducers should be avoided.

References (2)
  1. Cerner Multum, Inc. "Australian Product Information."
  2. (2020) "Product Information. Trodelvy (sacituzumab govitecan)." Immunomedics

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer